Registreer u om meldingen in te stellen voor instrumenten, economische gebeurtenissen en artikelen van de auteurs die u volgt.
Gratis registreren Heeft u al een account? Inloggen
Noteringen
Alle soorten instrumenten
- Alle soorten instrumenten
- Indexen
- Aandelen
- ETF's
- Fondsen
- Grondst.
- Valuta's
- Crypto
- Obligaties
- Certificaten
Probeer een andere zoekopdracht
Toegang tot premium-data: tot 50% korting InvestingPro BENUT DE SALE
Eaton Vance Worldwide Health Sciences Fund Class A (ETHSX)
Toevoegen/Verwijderen van een Portfolio
Voeg toe aan Portfolio
14,35
+0,04
+0,28%
- Beoordeling Morningstar:
- Totale activa: 715,71M
Eaton Vance Worldwide Health Sci A
14,35
+0,04
+0,28%
- Overzicht
- Profiel
- Historische Data
- Participaties
ETHSX Overzicht
Op deze pagina vindt u een uitgebreid profiel van Eaton Vance Worldwide Health Sciences Fund Class A. Kom meer te weten over onder meer het senior management, de totale activa, de investeringsstrategie en de contactgegevens van ETHSX.
Contact Informatie
Adres
Two International Place
Boston,MA 02110
United States
Boston,MA 02110
United States
Telefoon
+1 8008362414
Topmanagers
| Naam | Titel | Sinds | Tot |
|---|---|---|---|
| Jason A. Kritzer | Vice President | 2016 | now |
| Biografie | Mr. Kritzer is a Vice President of Eaton Vance. Prior to joining Eaton Vance in 2012, Mr. Kritzer was a director and equity analyst at BlackRock , Inc. covering the healthcare sector since 2006. | ||
| Samantha Pandolfi | Vice President | 2016 | now |
| Biografie | Ms. Pandolfi is a Vice President of EVAIL. Prior to joining EVAIL, Ms. Pandolfi held similar positions at EVMI. Prior to joining EVMI as a Vice President in November 2015, Ms. Pandolfi was a Portfolio Manager and Research Analyst with Goldman Sachs Asset Management over her fifteen year tenure (2000-2015). | ||
| Sven H. Borho | Founding General Partner | 2005 | 2016 |
| Biografie | Sven H. Borho, CFA, is a founding General Partner of OrbiMed. Mr. Borho is a portfolio manager for OrbiMed’s public equity funds and he heads the firm’s trading efforts. He started his career in 1991 when he joined Mehta and Isaly as a Senior Analyst covering European pharmaceutical firms and biotechnology companies worldwide. In 1993, Mr. Borho became portfolio manager to investment funds under management. Mr. Borho studied business administration at Bayreuth University in Germany and received a M. Sc. (Econ.) from The London School of Economics; he is a citizen of both Germany and Sweden. | ||
| Richard D. Klemm | Biotechnology Analyst | 2005 | 2016 |
| Biografie | Klemm joined OrbiMed in 2000 as a biotechnology analyst. Klemm has earned the right to use the Chartered Financial Analyst designation. | ||
| Geoffrey C. Hsu | Biotechnology Analyst | 2005 | 2016 |
| Biografie | Hsu joined OrbiMed in 2002 as a biotechnology analyst. Prior to joining OrbiMed, he worked as a financial analyst in the healthcare investment banking group at Lehman Brothers. Hsu has earned the right to use the Chartered Financial Analyst designation. | ||
| Trevor M. Polischuk | Analyst | 2005 | 2016 |
| Biografie | Polischuk joined OrbiMed in 2003 as an analyst covering the major global pharmaceutical industry. Previously, he worked at Lehman Brothers as a senior research analyst covering the U.S. pharmaceutical industry. | ||
| Samuel David Isaly | Portfolio Manager | 1985 | 2016 |
| Biografie | Samuel D. Isaly founded Exome in 2018 and is the Managing Member. Mr. Isaly is one of the world’s most recognized healthcare fund managers and has been active in global healthcare investing and analysis since 1968 when he joined Chase Manhattan Bank in New York. During his career, Mr. Isaly has been a pharmaceutical analyst with Chase Manhattan Bank, Merrill Lynch, Legg Mason, and S.G. Warburg. Isaly was a portfolio manager with OrbiMed Advisors. Previously, he was a president and partner with Mehta and Isaly Asset Management. From 1986 to 1989, he was a senior vice president with S.G. Warburg & Company. He also spent more than three years as a partner with Gramercy Associates, one and a half years as a vice president with Merrill Lynch & Company, and two years as a vice president with Chase Manhattan Bank. | ||
| Bernard Graham | - | 1985 | 1989 |
Laat weten wat u vindt van Eaton Vance Worldwide Health Sciences Fund Class A
Weet u zeker dat u deze grafiek wilt verwijderen?
Verwijderen Annuleren
Vervang de toegevoegde grafiek met een nieuwe grafiek?
Vervang Annuleren
Richtlijnen voor commentaar
Voeg Grafiek toe aan Commentaar
Blokkering bevestigen
Weet u zeker dat u %USER_NAME% wilt blokkeren?
Als u dit doet, kunnen u en %USER_NAME% geen publicaties meer van elkaar zien op Investing.com.
%USER_NAME% is toegevoegd aan uw lijst met geblokkeerde personen
Omdat u de blokkering van deze persoon net hebt opgeheven, moet u 48 uur wachten om hem/haar weer te kunnen blokkeren.
Rapporteer dit commentaar
Ik vind dit commentaar
Commentaar gemarkeerd
Bedankt!
Uw bericht is ter beoordeling verstuurd naar de moderatoren